Recombinant full-length parathyroid hormone (1-84): Profile report

BioDrugs

Volumn 21, Issue 3, 2007, Pages 205-208

  Moen, Marit D ^a   Scott, Lesley J ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; CALCITONIN; CALCIUM; IBANDRONIC ACID; PARATHYROID HORMONE[1-34]; PLACEBO; PREOTACT; RALOXIFENE; RECOMBINANT PARATHYROID HORMONE; RISEDRONIC ACID; UNCLASSIFIED DRUG; VITAMIN D;

BONE DENSITOMETRY; BONE METABOLISM; BONE TURNOVER; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CORTICAL BONE; DRUG EFFICACY; DRUG INDICATION; DRUG INDUCED HEADACHE; DRUG RESPONSE; DRUG TOLERABILITY; FRACTURE; HORMONE SUBSTITUTION; HUMAN; HYPERCALCEMIA; HYPERCALCIURIA; NAUSEA; NONHUMAN; OSSIFICATION; POSTMENOPAUSE OSTEOPOROSIS; PRIORITY JOURNAL; REVIEW;

AGED; FEMALE; HUMANS; MIDDLE AGED; OSTEOPOROSIS; OSTEOPOROSIS, POSTMENOPAUSAL; PARATHYROID HORMONE; RANDOMIZED CONTROLLED TRIALS; RECOMBINANT PROTEINS;

EID: 34249740174     PISSN: 11738804     EISSN: None     Source Type: Journal    
DOI: 10.2165/00063030-200721030-00009     Document Type: Review

References (27)

1. Moen MD, Scott LJ. Recombinant full-length parathyroid hormone (1-84). Drugs 2006; 66 (18): 2371-2381
2. Whitfield, J. Recombinant full-length parathyroid hormone (1-84): a viewpoint. Drugs 2006; 66 (18): 2382-2385
3. Hanley DA. Recombinant full-length parathyroid hormone (1-84): a viewpoint. Drugs 2006; 66 (18): 2382-2385
4. Hosking D. Recombinant full-length parathyroid hormone (1-84): a viewpoint. Drugs 2006; 66 (18): 2382-2385
5. Felsenberg D. Recombinant full-length parathyroid hormone (1-84): a viewpoint. Drugs 2006; 66 (18): 2382-2385
6. Raisz LG. Pathogenesis of osteoporosis: concepts, conflicts, and prospects. J Clin Invest 2005 Dec; 115 (12): 3318-25
7. Delmas PD, Rizzoli R, Cooper C, et al. Treatment of patients with postmenopausal osteoporosis is worthwhile. The position of the International Osteoporosis Foundation. Osteoporos Int 2005 Jan; 16 (1): 1-5
8. McClung M. Parathyroid hormone for the treatment of osteoporosis. Obstet Gynecol Surv 2004; 59 (12): 826-32
9. Murray TM, Rao LG, Divieti P, et al. Parathyroid hormone secretion and action: evidence for discrete receptors for the carboxyl-terminal region and related biological actions of carboxyl-terminal ligands. Endocr Rev 2005 Feb; 26 (1): 78-113
10. Nycomed. Preotact (full-length parathyroid hormone): product information (EU) [online]. Available from URL: http://www.emea.eu.int/humandocs/Humans/EPAR/ preotact/preotactM.htm [Accessed 2007 May 9]
11. Moreau IA, Smith SY, Guldberg RE, et al. Treatment of osteopenic rhesus monkeys with parathyroid hormone 1-84 for 16 months improves vertebral trabecular bone quantity and quality [abstract no. M415]. J Bone Miner Res 2005 Sep; 20 Suppl. 1: S412
12. Kimmel DB, Bozzato RP, Kronis KA, et al. The effect of recombinant human (1-84) or synthetic human (1-34) parathyroid hormone on the skeleton of adult osteopenic ovariectomized rats. Endocrinology 1993 Apr; 132 (4): 1577-84
13. 2 to stimulate femoral trabecular bone growth in ovariectomized rats. Calcif Tissue Int 1997 Jan; 60 (1): 26-9
14. Ejersted C, Andreassen TT, Oxlund H, et al. Human parathyroid hormone (1-34) and (1-84) increase the mechanical strength and thickness of cortical bone in rats. J Bone Miner Res 1993 Sep; 8 (9): 1097-101
15. Samnegard E, Iwaniec UT, Cullen DM, et al. Maintenance of cortical bone in human parathyroid hormone(1-84)-treated ovariectomized rats. Bone 2001 Mar; 28 (3): 251-60
16. Greenspan SL, Bone HG, Ettinger MP, et al. Effect of recombinant human parathyroid hormone (1-84) on vertebral fracture and bone mineral density in postmenopausal women with osteoporosis: a randomized trial. Treatment of Osteoporosis with Parathyroid Hormone Study Group. Ann Intern Med 2007 Mar 6; 146 (5): 326-39
17. Black DM, Bilezikian JP, Ensrud KE, et al. One year of alendronate after one year of parathyroid hormone (1-84) for osteoporosis. N Engl J Med 2005 Aug 11; 353 (6): 555-65
18. Black DM, Greenspan SL, Ensrud KE, et al. The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis. N Engl J Med 2003 Sep 25; 349 (13): 1207-15
19. Fogelman I, Christiansen C, Spector T, et al. Safety and efficacy of PTH(1-84) at 18 and 24 months in women with postmenopausal osteoporosis receiving hormone therapy: results from the POWER study [abstract no. 1080]. J Bone Miner Res 2005 Sep; 20 Suppl. 1: S21-2
20. Tregear GW, van Rietschoten J, Greene E, et al. Solid-phase synthesis of the biologically active N-terminal 1-34 peptide of the human parathyroid hormone. Hoppe Seylers Z Physiol Chem 1974; 355 (4): 415-421
21. Whitfield JF. Osteoporosis-treating parathyroid hormone peptides: What are they? What do they do? How do they do it? Curr Opin Invest Drugs 2006; 7 (4): 349-359
22. NPS® Pharmaceuticals. NPS receives approvable letter for PREOS NDA. 2006 Mar 10 [online]. Available from URL: http://www.npsp.com/news/releasetxt. php?ReqId=830043 [Accessed 2006 Nov 15]
23. 2 (ostabolin). Calcif Tissue Int 1996; 58 (2): 81-87
24. Vahle JL, Long GG, Sandusky, G, et al. Bone neoplasms in F344 rats given teriparatide [rhPTH(1-34)] are dependent on duration of treatment and dose. Toxicol Pathol 2004; 32 (4): 426-438
25. Morley P. Delivery of parathyroid hormone for the treatment of osteoporosis. Expert Opin Drug Deliv 2005; 2 (6): 993-1002
26. Hodsman AB, Bauer DC, Dempster DW, et al. Parathyroid hormone and teriparatide for the treatment of osteoporosis: a review of the evidence and suggested guidelines for its use. Endocr Rev 2005; 26 (5): 688-703
27. Hodsman A, Papaioannou A, Cranney A. Scientific Advisory Council of Osteoporosis Canada, Clinical Guidelines Committee, Writing Group on the Systematic Review of Parathyroid Hormone for the Treatment of Osteoporosis. Clinical practice guidelines for the use of parathyroid hormone in the treatment of osteoporosis. CMAJ 2006 Jul 4; 175 (1): 48